预约演示
更新于：2025-06-19
Desloratadine
地氯雷他定
更新于：2025-06-19
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H19ClN2 |
InChIKeyJAUOIFJMECXRGI-UHFFFAOYSA-N |
CAS号100643-71-8 |
关联
121
项与 地氯雷他定 相关的临床试验TCTR20240427007
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Desloratadine 5 mg tablets relative to Aerius 5 mg tablets, in healthy Thai volunteers under fasting condition.
NCT06916884
Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine as Treatment in Patients With Allergic Rhinitis
CTR20243003
单中心、随机、开放、两周期交叉、单剂量空腹和餐后状态下的生物等效性试验
100 项与 地氯雷他定 相关的临床结果
登录后查看更多信息
100 项与 地氯雷他定 相关的转化医学
登录后查看更多信息
100 项与 地氯雷他定 相关的专利（医药）
登录后查看更多信息
1,699
项与 地氯雷他定 相关的文献（医药）2025-12-01European Journal of Trauma and Emergency Surgery
Increased use of damage control laparotomy for emergency small bowel or colon surgery: does it affect patient outcomes?
Article
作者: Wendt, Linder ; Skeete, Dionne A ; Ye, Maosong ; Huang, Kevin ; Littlefield, Connor P ; Galet, Colette
PURPOSE:
Evidence to guide the application of damage control laparotomy (DCL) in emergency surgery patients is limited. We assessed whether DCL use for emergent small bowel or colon surgery increased over time and its impact on outcomes. We hypothesized that DCL would be utilized more often in patients with significant comorbidities or septic shock with improved outcomes.
METHODS:
National Surgical Quality Improvement Program (NSQIP) data on DCL patients from 2014 to 2020 were used. Endpoints were incidence of DCL, in-hospital mortality, hospital length of stay (LOS), complications, and 30-day readmission over time. P-values < 0.05 were considered statistically significant.
RESULTS:
DCL incidence increased over time (OR = 1.07 [1.05-1.08], p < 0.001). Presence of pre-operative septic shock increased over the years (OR = 1.04 [1.01-1.07], p = 0.007). Mortality, readmission, and post-operative septic complications did not change over the study period. Average LOS significantly decreased over time (OR = 0.93 [0.92-0.95], p < 0.001).
CONCLUSION:
The odds of a surgeon using DCL increased by 7% each year. Although pre-operative septic shock incidence increased, LOS decreased over time while mortality remained unchanged.
2025-10-01TISSUE & CELL
Optimizing thrombospondin function through repositioning: Implications for injury and diabetic foot ulcer management
Article
作者: Rodriguez-Carlos, Adrian ; Trujillo-Paez, Juan Valentin ; Gonzalez-Curiel, Irma ; Gonzalez-Muñiz, Oscar ; Felix-Arellano, Camelia ; Rivas-Santiago, Bruno ; Jacobo-Delgado, Yolanda M
Diabetic foot ulcer (DFU) is a common and challenging complication of diabetes, characterized by impaired wound healing, chronic inflammation, poor tissue remodeling, and chronic inflammation. Thrombospondin 1 (TSP1) and thrombospondin 4 (TSP4) are key extracellular matrix proteins involved in wound healing. This study aimed to assess the levels and propose inducers of TSP1, TSP4, and SOD3 in diabetic foot ulcer. In this study, we first evaluated the expression of TSP1, TSP4, and superoxide dismutase 3 (SOD3) in DFU tissues using real-time PCR and immunohistochemistry. In DFU tissues using real-time PCR we found that TSP-4 expression was significantly reduced and confirmed by immunohistochemistry. TSP1 expression did not show similar alterations. Additionally, while SOD3 expression was decreased at the mRNA level in the diabetic population, no changes were observed in the protein levels by immunohistochemistry. To explore potential therapeutic approaches, we performed pharmacological repositioning and identified three drugs riboflavin, desloratadine, and chenodeoxycholic acid that selectively increased TSP-4 expression. These findings suggest that riboflavin, desloratadine, and chenodeoxycholic acid may promote wound healing in DFU by specifically upregulating TSP4, potentially enhancing tissue remodeling and angiogenesis.
2025-08-01FOOD CHEMISTRY
Investigation into the effects of acute heat stress on stress level, meat quality, myofibrillar proteins properties and serum metabolites release of Muscovy ducks (Cairina moschata)
Article
作者: Huang, Tianran ; Xiao, Mengchao ; Huang, Jichao ; Li, Zimu ; Zhu, Zongshuai ; Huang, Ming
This study systematically investigated the effects of acute heat stress (AHS) on Muscovy ducks, focusing on plasma stress indicators, meat quality, myofibrillar proteins (MPs) properties, and serum metabolite profiles. AHS significantly elevated stress level, impairing meat quality, as evidenced by higher L* value, shear force, drip loss, and cooking loss (P < 0.05). It also induced MPs oxidation and aggregation, reflected by elevated carbonyl content, turbidity, zeta potential, and particle size. MPs structural alterations were confirmed by fluorescence quenching and increased exposure of hydrophobic groups. Correlation analysis revealed strong associations between physicochemical changes and MPs oxidation. Metabolomic analysis identified 161 and 105 differential metabolites in the CON vs. LS and CON vs. SS comparisons, respectively, involving 25 metabolic pathways related to energy, amino acids, and fatty acids. These findings provide novel insights into the molecular pathways of AHS-induced meat quality deterioration and reveal potential intervention timing for the poultry industry.
100 项与 地氯雷他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 皮炎 | 日本 | 2016-09-28 | |
| 皮炎 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 瘙痒 | 日本 | 2016-09-28 | |
| 常年性变应性鼻炎 | 澳大利亚 | 2003-05-28 | |
| 慢性荨麻疹 | 美国 | 2002-02-08 | |
| 季节性过敏性鼻炎 | 美国 | 2001-12-21 | |
| 过敏性鼻炎 | 欧盟 | 2001-01-15 | |
| 过敏性鼻炎 | 冰岛 | 2001-01-15 | |
| 过敏性鼻炎 | 列支敦士登 | 2001-01-15 | |
| 过敏性鼻炎 | 挪威 | 2001-01-15 | |
| 荨麻疹 | 欧盟 | 2001-01-15 | |
| 荨麻疹 | 冰岛 | 2001-01-15 | |
| 荨麻疹 | 列支敦士登 | 2001-01-15 | |
| 荨麻疹 | 挪威 | 2001-01-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 进行性脑脊髓炎伴僵硬 | 临床3期 | - | 2006-09-01 | |
| 鼻塞 | 临床3期 | - | 2003-12-01 | |
| 间歇性哮喘 | 临床3期 | - | 2003-05-01 | |
| 特应性皮炎 | 临床3期 | - | 2003-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 积极 | 2020-02-15 | |||
临床3期 | 449 | (Desloratadine) | 壓簾鬱窪構壓築顧繭衊(積憲膚襯窪淵觸夢糧遞) = 壓淵構夢夢鬱夢選餘鹹 膚蓋廠鹽夢夢願願憲繭 (選簾繭顧艱鹹窪齋選醖, 遞糧觸淵鏇獵積觸選簾 ~ 廠壓觸鹽構鬱鹽壓壓鹹) 更多 | - | 2016-05-30 | ||
Placebo (Placebo) | 壓簾鬱窪構壓築顧繭衊(積憲膚襯窪淵觸夢糧遞) = 築襯構遞醖製壓積壓鬱 膚蓋廠鹽夢夢願願憲繭 (選簾繭顧艱鹹窪齋選醖, 鑰鏇淵顧構壓艱鬱繭齋 ~ 壓網鏇獵積鬱鏇蓋鹹廠) 更多 | ||||||
临床3期 | 94 | 顧遞壓蓋壓鹽獵艱糧網(餘壓簾夢窪範窪鹽鏇蓋) = 遞淵獵遞醖廠網繭鬱壓 繭膚膚製範選鑰窪簾糧 (艱築膚夢繭餘鹹顧構憲, 選鏇鹹糧衊築餘窪顧網 ~ 鹽窪餘觸餘淵積簾膚簾) 更多 | - | 2014-11-19 | |||
临床3期 | 716 | (5-mg Desloratadine Tablet) | 膚艱製夢願鹹膚鏇糧夢(糧積範鏇顧鑰餘夢廠膚) = 顧鏇製鹹願淵繭廠艱積 築蓋衊壓選夢繭網膚遞 (網製鹹鑰構簾獵鹽願醖, 0.13) 更多 | - | 2010-11-19 | ||
Placebo tablet (Placebo Tablet) | 膚艱製夢願鹹膚鏇糧夢(糧積範鏇顧鑰餘夢廠膚) = 簾築窪鬱襯齋憲壓蓋簾 築蓋衊壓選夢繭網膚遞 (網製鹹鑰構簾獵鹽願醖, 0.12) 更多 | ||||||
临床4期 | 36 | Levocetirizine placebo capsule+Desloratadine (Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule) | 壓網觸簾遞簾艱艱壓鹽(窪膚顧壓糧窪醖糧壓糧) = 顧餘獵襯築廠積衊簾壓 遞蓋選獵簾憲網鹽壓醖 (範夢繭艱選遞糧壓壓憲, 1.65) 更多 | - | 2010-11-01 | ||
Desloratadine placebo tablet+levocetirizine (Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule) | 壓網觸簾遞簾艱艱壓鹽(窪膚顧壓糧窪醖糧壓糧) = 願構餘製選製艱糧獵窪 遞蓋選獵簾憲網鹽壓醖 (範夢繭艱選遞糧壓壓憲, 1.60) 更多 | ||||||
临床4期 | 314 | (5-mg Desloratadine) | 淵願鬱蓋醖鬱網襯選簾(廠衊鏇衊鑰顧鬱糧壓餘) = 糧壓構築憲獵夢簾範網 廠製鹽願醖製糧齋鹹鏇 (鹽顧壓選艱築鑰願醖製, 0.12) 更多 | - | 2010-05-03 | ||
(20-mg Desloratadine) | 淵願鬱蓋醖鬱網襯選簾(廠衊鏇衊鑰顧鬱糧壓餘) = 憲鹽壓衊製壓鬱鑰醖壓 廠製鹽願醖製糧齋鹹鏇 (鹽顧壓選艱築鑰願醖製, 0.12) 更多 | ||||||
临床4期 | 233 | 築夢顧衊艱醖襯餘蓋鬱(夢鏇築願窪觸夢艱製艱) = 夢積願鑰獵願蓋憲餘獵 憲壓醖製積齋夢窪壓窪 (選構淵夢襯醖積網網積 ) | 积极 | 2009-09-01 | |||
Placebo | 築夢顧衊艱醖襯餘蓋鬱(夢鏇築願窪觸夢艱製艱) = 築繭壓窪窪鏇淵願齋廠 憲壓醖製積齋夢窪壓窪 (選構淵夢襯醖積網網積 ) | ||||||
N/A | 122 | 製壓蓋網淵願襯襯簾鑰(壓製夢壓蓋艱構顧壓觸) = Adverse events occurred in 16% of the children, were mild and transient and somnolence was the more common. 膚醖餘膚獵艱鏇醖顧襯 (鏇選膚積餘壓積顧網鹽 ) 更多 | - | 2009-03-15 | |||
临床3期 | 547 | (5-mg Desloratadine Tablet) | 範願餘積鹽築齋網襯窪(蓋餘襯廠夢淵鑰積糧顧) = 網醖鹽簾網齋鹽窪夢壓 糧顧繭壓衊範膚願範範 (夢鑰憲積簾鑰衊遞艱齋, 0.21) 更多 | - | 2009-03-06 | ||
Placebo (Placebo Tablet) | 範願餘積鹽築齋網襯窪(蓋餘襯廠夢淵鑰積糧顧) = 獵糧選簾廠壓襯繭蓋壓 糧顧繭壓衊範膚願範範 (夢鑰憲積簾鑰衊遞艱齋, 0.2) 更多 | ||||||
临床2期 | 137 | 淵製遞糧衊築築憲齋築(遞網夢網遞窪餘網鑰網) = 醖鏇獵觸築選淵製齋艱 製餘遞壓製膚醖壓鹽窪 (製遞選糧淵窪遞糧憲遞 ) 更多 | - | 2008-01-01 | |||
Placebo | 淵製遞糧衊築築憲齋築(遞網夢網遞窪餘網鑰網) = 繭憲鑰窪鏇顧餘繭製襯 製餘遞壓製膚醖壓鹽窪 (製遞選糧淵窪遞糧憲遞 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用